Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.
Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.
Vaxxas Pty. Ltd. is an Australian company that specializes in the development and commercialization of innovative vaccine delivery technologies. Established in 2011 and headquartered in Sydney, with an additional office in Cambridge, Massachusetts, Vaxxas focuses on a needle-free delivery system known as the Nanopatch. This system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin, allowing for direct deposition of vaccines among a high concentration of immune cells. By targeting these immunological cells, Vaxxas aims to enhance the activation of the immune system and improve vaccine efficacy, thereby transforming the global landscape of vaccine administration.
Colorescience, Inc. specializes in the production and sale of mineral-based cosmetics and sunscreen products. Founded in 2000 and based in Carlsbad, California, the company offers a range of treatment products aimed at addressing various skin concerns, including pigmentation, redness, dark circles, and signs of aging, as well as catering to different skin types such as sensitive, oily, and dry skin. Its product line includes UV protectors, primers, foundations, and enhancers, all designed with high-quality ingredients and formulations. Colorescience distinguishes itself in the luxury aesthetic makeup market by focusing on efficacy and ease of use. The company distributes its products through a network of licensed physicians, luxury spas, retailers, and online channels, emphasizing its commitment to reducing skin cancer and other skin conditions.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Cleveland HeartLab, Inc. is a clinical reference laboratory dedicated to the prevention of cardiovascular disease (CVD) through innovative biomarker technologies and proprietary diagnostic tests. The company specializes in the early identification of individuals at risk for CVD, emphasizing the management and reduction of inflammation. Cleveland HeartLab provides a range of clinical laboratory services, including an inflammatory panel for CVD, an advanced CVD risk profile, and lipid testing. By focusing on novel molecular biomarkers, the company aims to enhance disease management and improve patient outcomes in cardiovascular health.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
GITR
Venture Round in 2012
GITR Inc. develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Private Equity Round in 2011
Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Mosaic Biosciences, Inc. is a company focused on developing biomaterials for tissue engineering applications, particularly synthetic extracellular materials that facilitate natural tissue regeneration. Based in Boulder, Colorado, and incorporated in 2009, Mosaic utilizes its proprietary technology platform to create novel scaffolds with specific biophysical and biochemical properties. These scaffolds are designed for a range of medical applications, including wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company's innovative approach aims to significantly advance the field of regenerative medicine and support the development of effective solutions for various medical needs. Mosaic Biosciences also collaborates strategically with Catalyst Biosciences to enhance its research and development efforts.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
Cleveland HeartLab, Inc. is a clinical reference laboratory dedicated to the prevention of cardiovascular disease (CVD) through innovative biomarker technologies and proprietary diagnostic tests. The company specializes in the early identification of individuals at risk for CVD, emphasizing the management and reduction of inflammation. Cleveland HeartLab provides a range of clinical laboratory services, including an inflammatory panel for CVD, an advanced CVD risk profile, and lipid testing. By focusing on novel molecular biomarkers, the company aims to enhance disease management and improve patient outcomes in cardiovascular health.
Aciex is focused on developing first-in-class products to fill unmet needs for ophthalmic therapeutics—products that will permit us to build a sustainable ophthalmic franchise. They believe their company is unique in both concept and products and timely in terms of the market, and they are pleased you have chosen to learn more about Aciex.
Vaxxas Pty. Ltd. is an Australian company that specializes in the development and commercialization of innovative vaccine delivery technologies. Established in 2011 and headquartered in Sydney, with an additional office in Cambridge, Massachusetts, Vaxxas focuses on a needle-free delivery system known as the Nanopatch. This system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin, allowing for direct deposition of vaccines among a high concentration of immune cells. By targeting these immunological cells, Vaxxas aims to enhance the activation of the immune system and improve vaccine efficacy, thereby transforming the global landscape of vaccine administration.
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.
Cool Energy, Inc. develops innovative systems that harness renewable energy to produce carbon-free power. The company is known for its ThermoHeart® Engine, which efficiently converts low-temperature waste heat from sources such as industrial exhaust, stationary power generators, and thermal pollution control systems into clean electricity. Operating at temperatures up to 700°C, these engines can generate up to 25 kilowatts of electrical power per module with impressive conversion efficiencies of nearly 30% in initial tests. The ThermoHeart® Engine is versatile, applicable in various settings including biomass, solar thermal, and geothermal energy systems. By utilizing advanced technologies and a novel Stirling cycle design, Cool Energy offers a low-maintenance, quiet, and highly efficient solution for energy recovery. Founded in 2006 and headquartered in Boulder, Colorado, the company began commercial shipments of its products to qualified customers in 2018.
NanoMR specializes in the development of blood diagnostic devices, focusing on the rapid isolation of rare cells from complex biological samples at concentrations as low as one cell per milliliter. The company's innovative immunomagnetic capture system allows for the simultaneous targeting of multiple cell types, enabling the efficient extraction of bacteria and fungi in cases of bloodstream infections, as well as specific cells such as circulating tumor or fetal cells. This process is completed in under 30 minutes, significantly enhancing the speed and accuracy of diagnostics in clinical settings.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
Apofore is focused on developing innovative therapeutics for Type 2 diabetes, utilizing Apolipoprotein A-IV (apo A-IV), a naturally occurring protein identified as a key regulator of insulin secretion and glucose homeostasis. The foundational research conducted by Dr. Patrick Tso at the University of Cincinnati underpins the company's approach, highlighting the potential of recombinant apo A-IV in managing diabetes. Currently, Apofore's lead therapeutic is in preclinical development, aiming to help patients effectively reduce blood sugar levels and enhance insulin secretion.
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition.
The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Anchor Therapeutics, Inc. is a biopharmaceutical company specializing in the design and development of peptide modulators for G protein-coupled receptors (GPCRs). The company focuses on creating Pepducin lipopeptide drug candidates that target the intracellular domains of GPCRs, allowing for allosteric modulation of GPCR signaling. Anchor Therapeutics aims to address various medical conditions, including cancer, inflammation, metabolic diseases, heart disease, and pain, through its innovative drug development platform. The company is engaged in pre-clinical research and offers internal programs targeting serious medical indications, such as diabetes and regenerative medicine. Originally incorporated as Ascent Therapeutics in 2006, the company rebranded to Anchor Therapeutics in 2010 and is located in Cambridge, Massachusetts.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
FoldRx Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing disease-modifying drug therapies for conditions related to protein misfolding and amyloidosis. The company’s pipeline includes advanced clinical programs targeting genetic neurological and cardiovascular disorders, specifically transthyretin-associated amyloidoses that affect both polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in early-stage discovery efforts aimed at addressing diseases such as Parkinson's and cystic fibrosis. Established in 2003 and headquartered in Cambridge, Massachusetts, the company aims to provide effective treatments for the accumulation of misfolded proteins caused by genetic mutations and deficiencies in cellular quality control mechanisms.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Seahorse Bioscience specializes in the development of analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company's flagship products include the Seahorse Extracellular Flux (XF) analyzers, which enable scientists to non-invasively measure the metabolic activity of cells. These instruments provide valuable insights into various cellular processes, including basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, facilitating research into mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including academic institutions, pharmaceutical and biotech companies, as well as OEM manufacturers of assay kits and laboratory instruments.
Arresto Biosciences, Inc., a biotechnology company, develops medicines to treat cancer and fibrotic diseases by targeting molecules from the extracellular matrix. The company was incorporated in 2007 and is based in Palo Alto, California.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
PharmAthene, Inc. is a biodefense company based in Annapolis, Maryland, that specializes in developing medical countermeasures aimed at preventing and treating the health impacts of biological and chemical weapons. Founded in 2001, the company is focused on creating innovative therapies that enhance safety, efficacy, and cost-effectiveness in healthcare. Its key products under development include Valortim, a monoclonal antibody designed for both prophylactic and therapeutic use against anthrax, and Protexia, a recombinant human butyrylcholinesterase intended for treating organophosphate poisoning resulting from exposure to chemical nerve agents. Through these efforts, PharmAthene aims to strengthen national health security.
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
Seahorse Bioscience specializes in the development of analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company's flagship products include the Seahorse Extracellular Flux (XF) analyzers, which enable scientists to non-invasively measure the metabolic activity of cells. These instruments provide valuable insights into various cellular processes, including basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, facilitating research into mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including academic institutions, pharmaceutical and biotech companies, as well as OEM manufacturers of assay kits and laboratory instruments.
Shape Pharmaceuticals, Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.
Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.
InfaCare Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing treatments for neonatal and pediatric patients. Founded in 2005 and headquartered in Trevose, Pennsylvania, the company is advancing its lead product, Stanate, which is designed to treat infantile jaundice, also known as hyperbilirubinemia. Stanate is a heme oxygenase inhibitor administered via a single intramuscular injection, targeting the breakdown of heme and inhibiting bilirubin production in both term and preterm newborns. This innovative approach aims to reduce the necessity for common interventions such as phototherapy and exchange transfusions, thereby improving care for vulnerable infant populations.
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.
Their mission is to provide you with personalized, high-quality care. They are dedicated to helping you through all aspects of your neurological and surgical care. From diagnosis to management, their team is at your service, ensuring our best, for you, each and every time.
Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed by leading stem cell researchers. Specialties Cellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single test from complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012.
MiddleBrook Pharmaceuticals is a pharmaceutical company offering anti-infective products and antibiotics.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Advancis is a pharmaceutical company focused on developing and commercializing novel anti-infective products.
They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition.
The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.
Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.
Ascent Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.
Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam's primary innovation lies in its small molecule, non-retinoid pharmacological chaperones, which target misfolded proteins within the retina. These pharmacological chaperones are designed to bind to misfolded rod opsin, a protein associated with retinitis pigmentosa, facilitating its proper trafficking to rod cell surfaces and outer segments. Through its research and development efforts, Bikam Pharmaceuticals aims to address critical unmet medical needs in the field of ophthalmology, particularly for rare genetic disorders that can lead to blindness.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.
Orqis Medical
Series D in 2007
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
RedPath Integrated Pathology, LLC operates as a reference laboratory and provides support services for oncology cases. It offers PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen. The company serves pathologists, clinicians, and patients. RedPath Integrated Pathology, LLC was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
FoldRx Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing disease-modifying drug therapies for conditions related to protein misfolding and amyloidosis. The company’s pipeline includes advanced clinical programs targeting genetic neurological and cardiovascular disorders, specifically transthyretin-associated amyloidoses that affect both polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in early-stage discovery efforts aimed at addressing diseases such as Parkinson's and cystic fibrosis. Established in 2003 and headquartered in Cambridge, Massachusetts, the company aims to provide effective treatments for the accumulation of misfolded proteins caused by genetic mutations and deficiencies in cellular quality control mechanisms.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
SkinMedica specializes in developing and commercializing a range of skin care products aimed at improving skin appearance and addressing dermatologic conditions. The company markets both prescription and non-prescription products primarily to physicians, focusing on aesthetic applications. Notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to reduce signs of aging and enhance overall skin health. SkinMedica's prescription product, VANIQA® Cream, is uniquely FDA-approved for reducing unwanted facial hair in women. Additionally, the company offers a variety of anti-aging products, moisturizers, sun protection, cleansers, and acne treatments. Colorescience Pro, a related brand, provides dermatologist-recommended cosmetics that address specific skin concerns while offering sun protection and environmental defense, available through physician and medical spa channels.
Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
SkinMedica specializes in developing and commercializing a range of skin care products aimed at improving skin appearance and addressing dermatologic conditions. The company markets both prescription and non-prescription products primarily to physicians, focusing on aesthetic applications. Notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to reduce signs of aging and enhance overall skin health. SkinMedica's prescription product, VANIQA® Cream, is uniquely FDA-approved for reducing unwanted facial hair in women. Additionally, the company offers a variety of anti-aging products, moisturizers, sun protection, cleansers, and acne treatments. Colorescience Pro, a related brand, provides dermatologist-recommended cosmetics that address specific skin concerns while offering sun protection and environmental defense, available through physician and medical spa channels.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
Antisoma is a biotechnology company specialising in the development of novel drugs for the treatment of cancer. It acquires promising early-stage drug candidates from academic and commercial institutions around the world, to manage the development of these drugs through preclinical testing and clinical trials, and to bring them to the market.
PharmAthene, Inc. is a biodefense company based in Annapolis, Maryland, that specializes in developing medical countermeasures aimed at preventing and treating the health impacts of biological and chemical weapons. Founded in 2001, the company is focused on creating innovative therapies that enhance safety, efficacy, and cost-effectiveness in healthcare. Its key products under development include Valortim, a monoclonal antibody designed for both prophylactic and therapeutic use against anthrax, and Protexia, a recombinant human butyrylcholinesterase intended for treating organophosphate poisoning resulting from exposure to chemical nerve agents. Through these efforts, PharmAthene aims to strengthen national health security.
SkinMedica specializes in developing and commercializing a range of skin care products aimed at improving skin appearance and addressing dermatologic conditions. The company markets both prescription and non-prescription products primarily to physicians, focusing on aesthetic applications. Notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to reduce signs of aging and enhance overall skin health. SkinMedica's prescription product, VANIQA® Cream, is uniquely FDA-approved for reducing unwanted facial hair in women. Additionally, the company offers a variety of anti-aging products, moisturizers, sun protection, cleansers, and acne treatments. Colorescience Pro, a related brand, provides dermatologist-recommended cosmetics that address specific skin concerns while offering sun protection and environmental defense, available through physician and medical spa channels.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Adheron Therapeutics, Inc. is focused on developing pharmaceuticals for the treatment of rheumatoid arthritis and fibrotic diseases, including pulmonary and skin fibrosis. The company is advancing its lead product, SDP051, a Cadherin-11 (Cad-11) antagonist that disrupts cell adhesion, thereby influencing protein production that can affect the cellular environment. This innovative approach aims to provide a next-generation, non-immunosuppressive treatment for fibrotic conditions and to address cartilage destruction associated with rheumatoid arthritis. Established in 2006 as Synovex Corporation, Adheron Therapeutics is based in Berkeley, California, and builds on research pioneered by Dr. Michael Brenner at Brigham and Women’s Hospital and Harvard Medical School. As of October 2015, Adheron operates as a subsidiary of Roche Holding AG.
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Orqis Medical
Series C in 2003
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).
Xanthus Pharmaceuticals Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, acquisition, and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.